Recombinant Human IFN-lambda 1/IL-29 Protein, N- His-SUMO

Interferon lambda 1 (IFN-λ1), also known as interleukin-29 (IL-29), is a member of the type III interferon family, which plays a crucial role in the immune response to viral infections. IFN-λ1 is particularly important in mediating antiviral activity in epithelial cells, making it a key player in the first line of defense against various pathogens, especially in the respiratory and gastrointestinal tracts. The significance of IFN-λ1 has been underscored by its ability to induce an antiviral state through the activation of specific receptors, leading to the upregulation of interferon-stimulated genes (ISGs) that inhibit viral replication. In recent years, research has focused on the therapeutic potential of IFN-λ1 in treating viral infections, such as hepatitis C virus (HCV) and more recently, SARS-CoV-2. Unlike traditional interferons (type I), IFN-λ1 is believed to have a more favorable safety and tolerability profile, as it primarily signals through the IL-28R receptor complex, which is expressed predominantly on epithelial cells. This cell-type specificity may reduce systemic side effects commonly associated with type I interferon treatments. Furthermore, studies have demonstrated that recombinant IFN-λ1 can enhance the immune response, offering a promising avenue for developing antiviral therapies and vaccines. As research progresses, understanding the molecular mechanisms of IFN-λ1 and its interaction with the immune system may provide insights into novel strategies for combating viral infections and modulating immune responses.